GET DAILY SIGNALSReplimune Group (REPL) Narrows Q2 Loss to $0.54 Per Share as Launch Gets Underway
Key Takeaways
- Replimune Group reported a net loss of $57.1 million, or $0.54 per share, for its fiscal second quarter ended September 30, 2026, narrowing from an $83.1 million loss a year earlier.
- The loss of $0.54 per share beat the analyst consensus estimate of roughly $0.78 per share by approximately $0.24.
- The company recorded no product revenue during the quarter, as its first commercial shipments of TUDRIQEV began in early October.
- Research and development (R&D) expense fell to $34.4 million, while selling, general and administrative (SG&A) expense was $21.9 million as the company built out its commercial organization.
- Replimune ended the quarter with $307.8 million in cash and cash equivalents, expected to fund operations for more than 12 months.
Earnings Context and Why It Matters
This report marks a pivotal transition for Replimune Group, a clinical-stage biotechnology company that is now becoming a commercial enterprise. The fiscal second quarter was the first full period following the U.S. Food and Drug Administration (FDA) accelerated approval of TUDRIQEV for certain patients with advanced melanoma. Because the company operates on a March fiscal year, this quarter ended September 30, 2026, falls within its fiscal 2027. With first commercial shipments beginning in early October, investors are watching closely to see whether early launch traction and disciplined spending translate into a sustainable commercial ramp. The results also offer an early read on how the company is managing costs while scaling its sales force and manufacturing capabilities. I checked a few comparable names in the sector using Tickeron’s AI Screener to get a sense of how Replimune stacks up on key metrics.
Reported Results
Replimune Group reported a net loss of $57.1 million, or $0.54 per basic and diluted share, for its fiscal second quarter ended September 30, 2026. That compares with a net loss of $83.1 million in the prior-year period. The result came in ahead of the analyst consensus estimate, which called for a loss of approximately $0.78 per share.
The company did not record product revenue during the quarter, as its first commercial shipments of TUDRIQEV occurred in early October. Management indicated it expects to report initial product revenue in the fiscal third quarter but is not providing formal revenue guidance.
On the cost side, R&D expense was $34.4 million, down from $57.9 million a year earlier. SG&A expense was $21.9 million, down from $26.4 million, though the figure reflects increased investment tied to commercial launch readiness, field hiring, and patient support programs. Replimune ended the period with $307.8 million in cash and cash equivalents, including roughly $141 million in net proceeds from an August 2026 equity offering. From what I see, the cash position provides a solid runway as the company moves into this new phase.
Market Reaction and Investor Sentiment
Replimune shares rose sharply following the release, gaining about 12.6% to reach roughly $14.70 as investors responded to the narrower-than-expected loss and early launch commentary. Sentiment has been building since the August accelerated approval of TUDRIQEV, which shifted the narrative from clinical development to commercial execution. Management reported that TUDRIQEV was first delivered to patients on October 6, with more than 15 institutions prescribing the therapy within the initial weeks. Analysts remain focused on the pace of adoption, reimbursement dynamics, and how early orders convert into recognized revenue. The market's reaction suggests investors are encouraged by the combination of a leaner cost structure and a commercial launch that is now underway.
Forward Outlook and Key Factors to Monitor
Looking ahead, the primary focus shifts to the commercial trajectory of TUDRIQEV and how quickly initial prescribing institutions convert into repeat orders. Management highlighted a target of roughly 200 priority accounts and noted that interest is extending beyond academic centers into community practices, with more than 50 meetings held with melanoma treaters to date.
Investors should monitor early adoption metrics, including the number of accounts ordering, the pace of patient starts, and reimbursement progress. Because TUDRIQEV's revenue may be recognized over multiple quarters in some cases, reported top-line figures could lag underlying demand signals in the near term.
On the clinical front, the company continues to enroll IGNYTE-3, the Phase 3 confirmatory study of TUDRIQEV plus nivolumab, and the REVEAL study in uveal melanoma. Cost discipline will also remain in focus, given the ongoing investments in the commercial launch and clinical programs. With a cash runway of more than 12 months, the company has time to demonstrate execution, but the pace of spending relative to early revenue recognition will be a key metric for investors to watch. I’m watching this closely as the launch data starts to come in.
Exploring AI Tools for Biotech Analysis
In my view, tools like Tickeron’s AI Screener can be helpful when evaluating names in the biotechnology space. The platform lets users apply filters for technical patterns, fundamentals, trends, and AI-driven signals across thousands of stocks and ETFs. It supports customizable scans by industry, market cap, volatility, and performance metrics, which can surface comparable opportunities or help refine a watchlist. For someone following Replimune Group, it offers one way to put the company’s metrics in context with peers without manual effort. I’ve found it useful for quick checks on sector trends and breakout candidates when building out research notes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for REPL turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 47 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +28.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.323) is normal, around the industry mean (3.151). P/E Ratio (-5.098) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement